A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia

AIMS: TAK‐041 (NBI‐1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G‐protein‐coupled receptor, has shown promise in preclinical studies for the treatment of symptoms associated with schizophrenia. Here, we report the results from a phase 1 study to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Wei, Han, David, Khudyakov, Polyna, Behrje, Rhett, Posener, Joel, Laurenza, Antonio, Arkilo, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544063/
https://www.ncbi.nlm.nih.gov/pubmed/35277995
http://dx.doi.org/10.1111/bcp.15305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544063/
https://www.ncbi.nlm.nih.gov/pubmed/35277995
http://dx.doi.org/10.1111/bcp.15305

Ejemplares similares